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Abstract 
Glioblastoma (GB) is a highly infiltrative tumor recurring within a few centimeters of the resection cavity in 
90% of cases, even in cases of complete tumor resection and adjuvant chemo/radiotherapy. We recently isolated 
GB-associated stromal cells (GASCs) from the GB peritumoral zone, with phenotypic and functional properties 
similar to those of the cancer-associated fibroblasts (CAFs) present in the stroma of carcinomas. In particular, 
GASCs promote blood vessel development and have tumor-promoting effects on glioma cells in vitro and in 
vivo. In this study, we characterized these cells further, by analyzing the transcriptome and methylome of 14 
GASC and five control stromal cell preparations derived from non-GB peripheral brain tissues. We identified 
two subtypes of GASCs in surgical margins in GB patients: GASC-A and GASC-B. GASC-B promoted the 
development of tumors and endothelium, whereas GASC-A did not. A difference in DNA methylation may 
underlie these two subtypes. We identified various proteins as being produced in the procarcinogenic GASC-B. 
Some of these proteins may serve as prognostic factors for GB and/or targets for anti-glioma treatment. In 
conclusion, in this era of personalized therapy, the status of GASCs in GB-free surgical margins should be taken 
into account, to improve treatment and the prevention of recurrence.  
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Introduction 
Glioblastoma (GB) has a poor prognosis, despite aggressive treatment by surgery, radiotherapy and 
chemotherapy [1, 2]. Even in cases of complete resection of the gadolinium-enhanced portion of the GB, 85% of 
recurrences occur in the resection margin [3]. Recurrence is thought to result from the proliferation of residual 
unresected tumor cells. Such cells have been isolated and shown to display alterations different from those of 
cells isolated from the corresponding tumor mass [4, 5]. In addition to containing unresected tumor cells, the 
tumor microenvironment may play a determinant role in local recurrence. It contains a number of different 
cellular elements, including inflammatory cells, endothelial cells and fibroblasts. Cancer-associated fibroblasts 
(CAFs), commonly referred to as myofibroblasts, constitute a significant component of the tumor stroma of 
carcinomas [6]. These cells have been shown to play an active role in reciprocal communication with tumor 
cells, thereby accelerating tumor growth and progression. We isolated a population of such stromal cells from 
the histologically normal surgical margins of GB by computer-guided stereotaxic biopsy and primary culture. 
We named these cells GB-associated stromal cells (GASCs). These cells were mostly located close to blood 
vessels. They were diploid, did not display the genomic alterations typical of GB cells and expressed markers 
associated with CAFs, including alpha-smooth muscle actin (αSMA), platelet-derived growth factor receptor-
beta (PDGFRβ/CD140b) and FSP1 [7, 8]. GASCs were also found to have tumor-promoting effects on glioma 
cells in vitro and in vivo and to have angiogenic properties [7, 8]. All these data suggest that GASCs may be a 
component of the vascular niche in surgical margins, establishing a permissive environment for angiogenesis 
and the proliferation of recurrence-initiating cells. 
In this study, we investigated the transcriptomes and methylomes of 14 GASC and five control stromal cell 
preparations derived from non-GB peripheral brain tissues. We identified two types of GASCs in surgical 
margins in GB patients: one subtype with, and the other without tumor-promoting and angiogenic properties. 
 
Materials and Methods 
Establishment of primary GASCs and control stromal cells 
The entire project was approved by the local institutional review board (CPP Ouest II) and the Direction 
générale de la santé (DGS). All patients undergoing surgery signed an informed consent form for participation 
in this study. Peripheral brain biopsy specimens were obtained from 14 patients with de novo GB and from five 
non-GB patients, for the propagation of primary GASCs and control stromal cells, respectively (Supplementary 
Table 1). Briefly, biopsy specimens were minced and mechanically dissociated in Dulbecco’s modified Eagles’ 
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medium-high glucose (DMEM-HG) (Lonza, Verviers, Belgium), as previously described [8]. The resulting 
suspension was used to seed T80 flasks (Nunc, Dominique Dutsher, Brumath, France) containing DMEM 
supplemented with 10% human AB serum (HABS) (EFS, Lyon, France) and 1% antibiotics (Sigma-Aldrich, 
Saint Quentin Fallavier, France), which was then incubated at 37°C in a humidified incubator, under an 
atmosphere containing 5% CO2. After several days, the outgrowth of spindle-shaped cells was observed. 
Experiments were performed with cells between passages 5 and 7. GASCs and control stromal cells were 
diploid, negative for the endothelial marker CD31 and the hematopoietic lineage markers (CD45, CD34), but 
positive for CAF-associated biomarkers, including αSMA, PDGFRβ and FSP1 (S100A4) (data not shown). 
Cell-line culture 
The aneuploid non-tumorigenic (A172) and diploid tumorigenic (U87MG) GB cell lines were provided by 
ATCC (LGC Promochem, Molsheim, France). They were maintained in the same medium as GASCs and 
control stromal cells at 37°C, under an atmosphere containing 5% CO2, until they reached 80 to 90% 
confluence. 
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza. Cells were cultured according 
to the supplier’s instructions, in endothelial cell growth medium-2 (EGM-2), corresponding to endothelial basal 
medium-2 (EBM-2) containing the supplements and growth factors of the EGM-2 SingleQuot kit (Lonza), in a 
humidified chamber at 37°C, under an atmosphere containing 5% CO2. 
Gene expression profiling and methylation analysis 
Total RNA and DNA were extracted with NucleoSpin RNAII and NucleoSpin Tissue kits, respectively 
(Macherey-Nagel, Hoerdt, France). Gene expression profiling was performed with the Agilent Whole Human 
Genome 8 × 60K Microarray Kit (Agilent Technologies, Santa Clara, USA) and DNA methylation profiling was 
performed with the Infinium Human Methylation 450 beadchip (Illumina Inc., San Diego, USA). For a detailed 
description of the gene expression profiling and methylation analysis, see Supplementary Methods.  
Phenotypic analysis by flow cytometry 
The following primary antibodies were used for flow cytometry: anti-CD146/MCAM, anti- PDGFRβ/CD140b, 
anti-ICAM1, anti-EGFR and isotype control antibodies from BD Biosciences (Le Pont de Claix, France); anti-
αSMA, anti-nestin and anti-NG2/CSPG4 antibodies from R&D Systems (Lille, France); and anti-
S100A4/FSP1, anti-THBS1 and anti-VASP antibodies from Abcam (Paris, France). The staining protocol used 
was as previously described [7, 8]. The stained cells were analyzed in a FACScan flow cytometer with 
CellQuest Software (BD Biosciences). 
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Preparation of conditioned media 
GASCs were grown to 70% to 80% confluence in DMEM-HG containing 10% HABS and 1% antibiotics. The 
medium was replaced with EBM-2 or DMEM-HG supplemented with 0.1% HSA and 0.2% antibiotics and the 
cells were cultured for a further 24 h. The resulting conditioned medium (CM) was centrifuged and stored at -
20°C for subsequent use. 
Functional analyses on GB cell lines 
Invasion assay 
Transwell inserts (Millicell cell culture inserts, 8 µm pore size) with a thin layer of Matrigel basement 
membrane matrix (BD Biosciences) were used to assess A172 cell invasion in response to factors secreted by 
GASCs. Briefly, A172 cells (5 × 104 cells) were added to the upper chamber, and 500 µl of negative control 
medium (DMEM-HG supplemented with 0.1% HSA and 0.2% antibiotics), positive control medium (10% 
HABS) or GASC-CM was added to the bottom chamber. After 6 h, the cells that had migrated to the underside 
of the insert membrane After 6 h, the cells that had invaded to the underside of the insert membrane were 
stained with hematoxylin and counted with a computerized image-analysis system (MetaView, Roper Scientific, 
Evry, France). Six fields per insert, at a magnification of ×200, were used to count the cells that had invaded. 
Cell invasion values are expressed as means ± SEM of the percentage of cells invading in the different 
conditions. 
In vitro proliferation assay 
We assessed the ability of GASCs to affect the proliferation of GB cells, using the aneuploid glioma cell line 
A172, to make it possible to distinguish between tumor cells and diploid GASCs. GASCs were used to seed six-
well plates, at a density of 96 × 103 cells per well, and were cultured in DMEM supplemented with 10% HABS 
and 1% antibiotics for 24 h. We then added 96 × 103 A172 cells per well. The cells were cocultured for three 
days and then harvested. We used Vindelov’s protocol to stain chromosomal DNA [9] and the cells were 
analyzed by flow cytometry with a FACScan flow cytometer (BD Biosciences). We calculated the DNA index 
(DI) and the percentages of the cell populations in each culture, as determined on the basis of their DNA 
content, with Modfit version 5.2 software (Verity Software House, Topsham, Maine), as previously described 
[10]. Cell-cycle analysis was carried out on the aneuploid A172 cells, and the proliferation index (PI) of these 
cells was evaluated as the percentage of cells in S+G2M phase. 
In vivo implantation 
Female Swiss nude mice (8-10 weeks old) were obtained from Charles River Laboratories (L’Arbresle, France). 
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The protocol was approved by the Committee on the Ethics of Animal Experiments of the "Pays de la Loire" 
(Permit Number: CEEA.2010.45). U87MG cells were subcutaneously injected into the right flank alone (0.5 × 
106 cells, n = 7) or together with 0.5 × 106 GASCs [GASC-A (GASC-31); n = 5 or GASC-B (GASC-3); n = 4]. 
Tumor volume within the flank was determined by direct measurement with a digital caliper, twice weekly, and 
was calculated as follows: 0.5 × (largest diameter) × (smallest diameter)2.  
Functional analyses on HUVECs 
Migration assay 
Transwell inserts (Millicell cell culture inserts, 8 µm pore size, Millipore) were used to assess the migration of 
HUVECs in response to factors secreted by GASCs. For these experiments, HUVECs (2.5 × 104 cells) were 
added to the upper chamber, and 500 µl of negative control medium (EBM-2 with 0.1% HSA and 0.2% 
antibiotics), positive control medium [10% foetal calf serum (FCS)] or GASC-CM was added to the bottom 
chamber. After 6 h, the cells that had migrated to the underside of the insert membrane were stained and counted 
with a computerized image-analysis system, as described above. 
Proliferation assay 
HUVECs (1 × 104 cells/cm2) were plated in 96-well plates. They were incubated for 48 h, after which, the 
culture medium was replaced with 100 µl of negative control medium (EBM-2 supplemented with 0.1% HSA 
and 0.2% antibiotics), positive control medium (EGM-2) or GASC-CM. The plate was incubated for 72 h. The 
medium was then removed from the wells and the plate was stored at -80°C until the assay was carried out. Cell 
survival was estimated with the CyQUANT® cell proliferation assay kit, according to the manufacturer’s 
instructions (Fisher Scientific, Illkirch, France). Sample fluorescence was measured with a microplate reader 
(Fluoroskan Ascent FL, Labsystem, Cergy-Pontoise, France). The fluorescence of HUVECs incubated with the 
negative control medium was considered to correspond to 100% survival. 
Endothelial tubule formation 
HUVECs (5 × 104 cells/cm2) were used to seed 96-well plates coated with Matrigel basement membrane matrix 
(50 µl/well, BD Biosciences), and were incubated for 6 h in EBM-2 negative control medium, EGM-2 positive 
control medium or GASC-CM. The length of the endothelial tubule in each field was quantified with Image J 
software. Data are expressed as means ± SEM. 
Statistical analysis 
Results are expressed as means ± SEM. The Kruskal-Wallis test was used for statistical analyses. Differences 
were considered significant if P < 0.05. 
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Results 
Gene expression profiles identify two subgroups of GASCs derived from GB 
We performed an unsupervised hierarchical clustering analysis of group samples according to their 
transcriptomic profile (4122 selected probes with an SD ≥ 0.5). The results of the clustering analysis are 
presented in the dendrogram in Figure 1a. We observed that the samples are clustered into two main groups: 
group A, corresponding to four GASC samples and three control stromal cell samples derived from two patients 
with epilepsy and one patient with an epidermoid cyst, and group B, corresponding to 10 GASC samples and 
two control stromal cell samples derived from a patient with meningioma and a patient with craniopharyngioma 
(Figure 1a). Genome-wide methylation profiling gave the same clustering pattern (Figure 1b). Given the 
heterogeneity of the control stromal cells, we decided to limit our comparisons to group A GASCs (GASC-A) 
and group B GASCs (GASC-B) in this study. 
Genes differentially expressed between GASC-A and GASC-B 
We found that 895 (713 genes) of the 4122 probes selected were differentially expressed between GASC-A and 
GASC-B: 422 probes (339 genes) were overexpressed and 473 probes (374 genes) were underexpressed in 
GASC-B (Supplementary Table 2). Hierarchical cluster analysis of the 895 differentially expressed probes 
clustered GASC samples into GASC-A and GASC-B groups, as in the unsupervised cluster analysis (data not 
shown). Functional annotation of the differentially expressed genes (NIH-David software) showed enrichment 
in several Gene Ontology biological processes (Fisher’s exact test): cell division, nervous system development, 
blood vessel development, inflammatory response, epidermal growth factor receptor signaling pathway, cell 
motion and muscle system processes (Table 1). 
We found that 80 of the 339 (24%) overexpressed genes were hypomethylated in GASC-B and 85 of the 374 
(23%) underexpressed genes were hypermethylated in GASC-B (Supplementary Table 2). The differentially 
methylated genes corresponding to the biological term enrichments described above are indicated in Table 1. 
Validation of transcriptomic data for the selected genes 
The differential expression of six genes was confirmed by flow cytometry analyses: GASC-B overexpressed the 
VASP, nestin, THBS1 and CSPG4/NG2 genes and underexpressed the EGFR and ICAM1 genes (Figure 2). We 
also found that the expression of other myofibroblast- or CAF-associated markers, including αSMA, 
PDGFRβ/CD140b and S100A4/FSP1, was stronger in GASC-B than in GASC-A (Figure 2). These markers 
were previously shown to be more strongly expressed in GASCs than in control stromal cells [7]. 
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Tumor-promoting properties of the two subgroups of GASCs 
We investigated whether the two subtypes of GASCs identified by transcriptome analysis were associated with 
different tumor-promoting properties, such as invasion and proliferation, using the aneuploid A172 GB cell line. 
GASC-CM resulted in a greater invasion capacity of A172 cells than culture in the positive control medium 
(10% HABS) (Figure 3a). No significant difference was observed between the two subgroups of GASCs. No 
invasion by A172 cells was observed in the presence of the negative control medium (data not shown). The 
addition of GASC-B to the aneuploid A172 cell line induced an increase in tumor cell proliferation, which was 
significantly stronger than after the addition of GASC-A (Figure 3b). This result was validated in vivo, with the 
diploid tumorigenic U87MG cell line. The subcutaneous injection into nude mice of GASC-B together with the 
U87MG cell line resulted in a significantly higher tumor volume induction than the injection of U87MG cells, 
either alone or in together with GASC-A (Figure 3c). 
Endothelium-promoting abilities of the two subgroups of GASCs 
We assessed the effect of the two subgroups of GASCs on the migration, proliferation and tubule formation of 
endothelial cells (Figure 4). We found that both subgroups of GASCs induced slightly higher levels of 
endothelial cell migration and proliferation than the negative control medium (Figure 4a and 4b). No significant 
difference was observed between the two subgroups of GASCs. In tubule formation assays, GASC-B  resulted 
in significantly longer tubules (175.4 ± 2.1 µm) than GASC-A (151.7 ± 4.6 µm) and the negative control 
medium (158.7 ± 4.9 µm) (Figure 4c and 4d). 
 
Discussion 
In this study, we identified two subtypes of GASCs in the histologically normal surgical margins of GB patients: 
GASC-A and GASC-B. The genes differentially expressed between the two subtypes were significantly 
associated with cell division, blood vessel development and muscle system processes. The GASC-B subtype, 
corresponding to 71% of the GASC samples analyzed, displayed the characteristics of GASCs described in our 
previous studies [7]. This subtype had a myofibroblast phenotype and procarcinogenic properties. In particular, 
unlike the GASC-A subtype, it promoted GB cell growth in vitro and in vivo and increased the tube length of 
HUVECs, suggesting that it also had angiogenic properties. The GASC-B subtype did not appear to be specific 
to the GB microenvironment, as its transcriptome closely resembled those of control stromal cells derived from 
meningioma and craniopharyngioma. These CNS diseases are considered to display benign biological behavior, 
but they may present an infiltrative pattern and recur more frequently than other benign tumors [11, 12]. 
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The cells of the GASC-B subtype overexpressed several markers, such as CSPG4/NG2, a transmembrane 
chondroitin sulfate, CD146/MCAM, a cell adhesion molecule, and nestin, a neural stem cell marker that we 
previously showed to be more strongly expressed in GASCs than in control stromal cells [7]. These molecules 
have been shown to be attractive potential biomarkers of cancer prognosis. For example, CSPG4/NG2 has been 
proposed as a prognostic marker for breast cancers [13], head and neck squamous cell carcinomas (HNSCC) 
[14] and gliomas [15, 16]. The expression of nestin has been described in tumor and peritumor areas of GB, 
independently of the presence of neoplastic cells [17, 18]. Nestin expression has been shown to increase with 
malignancy grade, and high levels of nestin are associated with poor survival [19, 20]. CD146 is abnormally 
expressed in various tumors and is closely associated with tumor progression [21, 22]. CSPG4/NG2, nestin and 
CD46 are also potentially attractive targets for cancer treatment [21, 23, 24]. 
In this study, genome-wide methylation profiling and gene expression profiling gave the same clustering pattern, 
suggesting that the GASC-B phenotype may result from DNA methylation. Several studies have highlighted the 
importance of this epigenetic mechanism in the regulation of myofibroblast differentiation [25] and in the 
maintenance of cancer-associated fibroblast properties [26–29]. The genes differentially methylated between 
GASC-A and GASC-B included CSPG4/NG2 and CD146, which were hypomethylated in GASC-B, resulting in 
their overexpression. Changes in the expression of CSPG4/NG2 due to hypomethylation have already been 
reported for the stroma of human colon carcinoma [30] and in HNSCC [14]. Conversely, ICAM-1 and EGFR 
were found to be hypermethylated in GASB-B, and this hypermethylation was associated with the 
underexpression of these genes. ICAM1 silencing by epigenetic regulation has been described in tumor 
endothelial cells, rendering these cells unresponsive to inflammatory activation [31]. EGFR hypermethylation 
has been described in a subset of tumors, including GB, breast, colon and lung cancers [32, 33], and may play a 
role in determining the efficacy of anti-EGFR treatments [33, 34]. In addition to DNA methylation, other 
mechanisms involved in myofibroblast differentiation, including Wnt, Notch and hedgehog signaling, TGF-β 
and other types of epigenetic regulation, such as histone acetylation and/or small interfering RNAs [25], may 
induce the GASC-B phenotype. 
Our findings indicate that two extratumoral microenvironments can be encountered in GB patients: an 
extratumoral microenvironment containing GASCs with procarcinogenic properties and another containing 
GASCs without such properties. In accordance with our findings, Roman-Pérez et al., (2012) [35] reported the 
presence of two different subtypes of extratumoral microenvironment influencing the aggressiveness and 
outcome of human breast cancers. Furthermore, in 2013, Al Rakan et al. [36] carried out molecular and cellular 
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characterizations of breast stromal fibroblasts (TCFs) from negative surgical margins. TCFs closely resemble 
GASCs in terms of their carcinogenic properties and patient-to-patient variability.  
All these data indicate that the tumor microenvironment present after resection may play a determinant role in 
local recurrence. Consistent with this possibility, several studies have highlighted the importance of surgical 
margin status for determining the likelihood of local relapse [3, 37]. Pirrotte et al. (2009) [38] reported longer 
survival in patients undergoing complete resection of the area of increased tracer uptake on PET, whereas 
complete resection of the gadolinium-enhanced MR-delineated area did not affect survival, suggesting that 
metabolic PET may be a more useful presurgical imaging technique. Intraoperative tumor identification in 
fluorescence-guided surgery with 5-aminolevulinic acid (ALA) is also an emerging technique that increases the 
rate of complete resections and extends survival [39, 40]. In this era of personalized therapy, the characterization 
of tumor cells and the status of GASCs located in GB surgical margins should be taken into account, to improve 
the efficacy of treatment and the prevention of recurrence. 
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Figure legends 
Figure 1: Hierarchical clustering dendrograms showing gene expression (a) and DNA methylation (b) data from 
GASCs and control stromal cells. In the dendrogram, the samples or groups (clusters) of samples with similar 
expression patterns are linked by branches. The vertical axis of the dendrogram represents the distance 
(dissimilarity) between samples or clusters of samples. The length of the each branch is correlated with size of 
the difference between the samples it connects. Two main clusters of samples are observed: group A, 
corresponding to four GASC samples and three control stromal cell samples derived from two patients with 
epilepsy and one patient with an epidermoid cyst, and group B, corresponding to 10 GASC samples and two 
control stromal cell samples derived from a patient with meningioma and a patient with craniopharyngioma. 
 
 
 
Figure 2: Phenotypic analysis by flow cytometry of GASC-A (n = 4) and GASC-B (n = 4). GASCs were 
immunostained with antibodies against CAF-associated markers (αSMA, CD140b, S100A4, CD146 and 
CSPG4), nestin, THBS1, VASP, EGFR and ICAM1. Results are expressed as means ± SEM of the fold-change 
ratio of the geometric mean marker-positive/geometric mean isotype control-positive cells and as means ± SEM 
of the difference between marker- and isotype control-positive cells (*, P < 0.05 between GASC-A and GASC-
B). 
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Figure 3: (a) HABS or CM from GASC-A and GASC-B was added to the lower compartments of 24-well 
plates. A172 cells (5 x 104) were used to seed the Transwell inserts and the plates were incubated for 6 h. The 
percentage cells invading the lower comparment is presented (means ± SEM; * P < 0.05 versus HABS). (b) 
Direct coculture assay of GASC-A or GASC-B with the aneuploid glioma cell line A172. Bar graphs show 
means ± SEM of the PI fold-change between A172 cells cultured alone and A172 cells cocultured with GASCs 
(*, P = 0.001 between GASC-A and GASC-B). (c) U87MG cells were injected alone (n = 7) or co-injected with 
GASC-A (n = 5) or GASC-B (n = 4) subcutaneously into nude mice. Tumor volume is plotted for the days 
indicated, as the median ± SEM (*, P = 0.008, versus U87MG alone). 
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Figure 4: (a) EBM-2, FCS or CM from GASC-A and GASC-B was added to the lower compartments of 24-well 
plates. HUVECs (2.5 x 104) were used to seed Transwell inserts and the plates were incubated for 6 h. The 
percentage of cells migrating is presented (means ± SEM; * P < 0.05 versus EBM-2). (b) Effect of GASCs on 
the survival of HUVECs. The cells were incubated for 3 days with EBM-2, EGM-2 or CM from GASC-A or 
GASC-B. The percentage of cells surviving is presented (means ± SEM; * P < 0.05 versus EBM-2). (c) and (d) 
Effect of GASCs on tube length. (c) Phase-contrast micrographs of HUVEC tube formation on Matrigel. 
HUVECs were used to seed Matrigel and were incubated at 37°C for 6 h in EBM-2, EGM-2 or CM from 
GASC-A or GASC-B (scale bar = 100 µm). (d) Tube length was used to quantify angiogenesis. Results are 
means ± SEM (* P = 0.049 versus EBM-2 or CM from GASC-A). 
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Table 1: GO biological process enrichment of the genes differentially expressed between GASC-A and GASC-B. Genes overexpressed in GASC-B are shown in bold. The 
remaining genes were underexpressed in GASC-B. Genes highlighted in gray correspond to genes overexpressed and hypomethylated in GASC-B or underexpressed and 
hypermethylated in GASC-B. 
GO:0008150_biological_process  P-value  Genes 
GO:0051301_cell division  3.56 10-6  CABLES1, C13ORF34, C14ORF106, CCNE2, CDK6, CDKN2A, CENPH, CENPJ, CKS1B, 
ESPL1, FBXO5, HAUS8, HELLS, KIF20B, KNTC1, LIG1, MAD2L1, MCM5, NCAPD2, 
NCAPD3, NCAPG2, NEK1, NUF2, PARD3, PTTG1, PTTG2, RACGAP1, SKA3, SMC2, 
SMC4, ZWINT  
GO:0007399_nervous system development  4.05 10-4  APOE, ARNT2, BAI2, BAIAP2, BEX1, C17ORF28, C1S, CABLES1, CDK5R1, CDK6, 
CDKN1C, CLDN1, CLU, CXCL1, DCLK1, DLC1, DOK5, EFHD1, EFNB1, EGFR, EPOR, 
FEZ1, FGF5, GBX2, GFRA1, HEYL, INA, KCNMA1, L1CAM, LMO4, MAFB, MEF2C, 
MSX1, NEFM, NES, NRGN, NTRK2, PARD3, PBX1, PHGDH, PLXNB1, PTK2B, PTN, 
RACGAP1, RCAN2, RELN, RGS9, RTN1, RUNX3, SEMA5B, SEPP1, SERPINE2, 
SERPINF1, SLITRK4, SMAD1, TBX3, TIAM1, TIMP3, TRIM3, UCHL1, VASP, VLDLR, 
XRCC2, ZEB1, ZIC5 
GO:0001568_blood vessel development  7.38 10-5  ARHGAP22, APOE, CCBE1, CSPG4, EREG, FOXO1, GBX2, GJA4, GJC1, LAMA4, 
LMO2, LOX, NTRK2, PDGFA, PLCD3, PLXDC1, PLXND1, PTK2B, RECK, SEMA3C, 
TBX3, TGM2, THBS1, TIPARP 
GO:0006954_inflammatory response  0.026  AOC3, C1R, C1RL, C1S, C2, C4B, CD14, CD55, CDO1, CFB, CFD, CLU, CXCL1, CYBA, 
IL17B, IL17D, IL20RB, NUPR1, S1PR3, SMAD1, THBS1 
GO:0007173_epidermal growth factor 
receptor signaling pathway 
 0.021  EGFR, EREG, HBEGF, PLCE1, PTK2B 
GO:0051270_regulation of cell motion  0.003  APOE, DLC1, EGFR, ENPP2, HBEGF, ICAM1, IGFBP3, IGFBP5, LAMA4, MYLK2, 
PARD3, PDGFA, PTK2B, PTPRU, SERPINE2, THBS1, TRIB1 
GO:0003012_muscle system process  0.029  CYBA, GAA, GJC1, GUCY1A3, KCNMA1, MYH11, MYLK2, MYOM1, SCN5A, SLMAP, 
SMTN, TNNT2, VIPR1 
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